All In Biotech

Free tool

FAERS Monitor: Tykerb

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022059 or its brand name (Tykerb, Lapatinib Ditosylate). Reports on generic versions are filed under their own applications.

Reports

15,452

Serious

10,580

68% of reports

Hospitalization

4,015

Death reported

2,486

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • diarrhoea4,173
  • nausea1,616
  • death1,463
  • fatigue1,309
  • vomiting1,211
  • rash1,062
  • disease progression1,007
  • palmar-plantar erythrodysaesthesia syndrome931
  • asthenia607
  • malignant neoplasm progression565
  • drug ineffective561
  • dyspnoea561
  • pyrexia528
  • dehydration525
  • decreased appetite519

Reports by year received

View as table
YearReports
20059
200614
2007936
2008744
20091,056
20101,246
20111,667
20121,539
20131,479
20141,035
20151,102
2016532
2017721
2018635
2019674
2020706
2021356
2022240
2023253
2024297
2025145
202666

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,707 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
palmar-plantar erythrodysaesthesia syndromeSignal93156.653.148,800
disease progressionSignal1,00711.711.09,790
diarrhoeaSignal4,1738.98.629,776
malignant neoplasm progressionSignal5657.57.03,200
dehydrationSignal5255.44.91,870
vomitingSignal1,2113.53.32,218
rashSignal1,0623.33.11,753
decreased appetiteSignal5193.02.8718
nauseaSignal1,6162.82.71,912
deathSignal1,4632.32.21,135
fatigueSignal1,3092.32.2986
astheniaSignal6072.22.0402
pyrexiaSignal5282.11.9299
dyspnoea5611.31.252
drug ineffective5610.60.5182

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.